



FINANCIAL STATEMENTS
JUNE 30, 2017 AND 2016
AND REPORT ON COMPLIANCE
JUNE 30, 2017

CONTENTS

	Page
INDEPENDENT AUDITORS' REPORT	1 - 2
FINANCIAL STATEMENTS	
Statements of Financial Position	3
Statements of Activities	4 - 5
Statements of Cash Flows	6
Notes to Financial Statements	7 - 18
SUPPLEMENTARY INFORMATION AND REPORT ON COMPLIANCE	
Schedules of Functional Expenses	19 - 20
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	21 - 22

INDEPENDENT AUDITORS' REPORT

Families of SMA d/b/a Cure SMA
Elk Grove Village, Illinois

We have audited the accompanying financial statements of Families of SMA d/b/a Cure SMA, which comprise the statements of financial position as of June 30, 2017 and 2016, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatements of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion


In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Families of SMA d/b/a Cure SMA as of June 30, 2017 and 2016, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Report on Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The schedules of functional expenses are presented on pages 19 to 20 for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated November 7, 2017, on our consideration of Families of SMA d/b/a Cure SMA's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Families of SMA d/b/a Cure SMA's internal control over financial reporting and compliance.



Kaufman, Rossin & Co., P.A.

November 7, 2017
Miami, Florida

FAMILIES OF SMA d/b/a CURE SMA
STATEMENTS OF FINANCIAL POSITION
JUNE 30, 2017 AND 2016

ASSETS	2017	2016
CURRENT ASSETS		
Cash and cash equivalents	\$ 3,126,401	\$ 2,658,075
Receivables, net (Note 4)	536,684	166,327
Prepaid expenses	49,845	16,416
Total current assets	3,712,930	2,840,818
INVESTMENTS (NOTES 2 AND 7)	1,032,313	854,008
OTHER ASSETS	23,342	6,344
PROPERTY AND EQUIPMENT, NET (NOTE 5)	215,957	215,630
	\$ 4,984,542	\$ 3,916,800
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Accounts payable and accrued expenses	\$ 1,299,429	\$ 622,416
Grants payable (Note 6)	762,500	735,000
Total current liabilities	2,061,929	1,357,416
GRANTS PAYABLE (NOTE 6)	227,500	243,750
COMMITMENTS AND CONTINGENCIES (NOTE 9)		
NET ASSETS (NOTE 7)		
Unrestricted	1,212,123	1,186,315
Temporarily restricted	484,392	305,881
Permanently restricted	998,598	823,438
Total net assets	2,695,113	2,315,634
	\$ 4,984,542	\$ 3,916,800

See accompanying notes.

FAMILIES OF SMA d/b/a CURE SMA
STATEMENT OF ACTIVITIES
YEAR ENDED JUNE 30, 2017

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
SUPPORT, REVENUE, GAINS AND INVESTMENT RETURN				
Contributions and chapter event related revenue	\$ 5,487,877	\$ 627,507	\$ 116,736	\$ 6,232,120
Annual conference	1,061,543	-	-	1,061,543
Industry collaboration income	320,298	-	-	320,298
Other income	171,918	-	-	171,918
Investment income, net (Note 3)	3,145	-	84,709	87,854
Net gain from non-recurring licensing agreement	585,000	-	-	585,000
Net assets released from restrictions	475,281	(448,996)	(26,285)	-
Total support, revenue, gains and investment return	8,105,062	178,511	175,160	8,458,733
EXPENSES				
Program Services:				
Research (Note 6)	3,099,625	-	-	3,099,625
Patient services	949,094	-	-	949,094
Family support	1,414,116	-	-	1,414,116
Awareness	767,242	-	-	767,242
Total program services	6,230,077	-	-	6,230,077
Supporting Services:				
General and administrative	329,533	-	-	329,533
Fundraising and event related	1,519,644	-	-	1,519,644
Total supporting services	1,849,177	-	-	1,849,177
Total expenses	8,079,254	-	-	8,079,254
CHANGE IN NET ASSETS	25,808	178,511	175,160	379,479
NET ASSETS - BEGINNING	1,186,315	305,881	823,438	2,315,634
NET ASSETS - ENDING	\$ 1,212,123	\$ 484,392	\$ 998,598	\$ 2,695,113

See accompanying notes.

FAMILIES OF SMA d/b/a CURE SMA
STATEMENT OF ACTIVITIES
YEAR ENDED JUNE 30, 2016

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total
SUPPORT, REVENUE AND INVESTMENT RETURN				
Contributions and chapter event related revenue	\$ 5,067,313	\$ 357,442	\$ 112,008	\$ 5,536,763
Annual conference	706,089	-	-	706,089
Industry collaboration income	103,831	-	-	103,831
Other income	183,494	-	-	183,494
Investment income, net (Note 3)	22	-	512	534
Net assets released from restrictions	367,177	(367,177)	-	-
Total support, revenue and investment return	6,427,926	(9,735)	112,520	6,530,711
EXPENSES				
Program Services:				
Research (Note 6)	2,112,946	-	-	2,112,946
Patient services	662,833	-	-	662,833
Family support	1,192,837	-	-	1,192,837
Awareness	678,031	-	-	678,031
Total program services	4,646,647	-	-	4,646,647
Supporting Services:				
General and administrative	277,608	-	-	277,608
Fundraising and event related	1,352,035	-	-	1,352,035
Total supporting services	1,629,643	-	-	1,629,643
Total expenses	6,276,290	-	-	6,276,290
CHANGE IN NET ASSETS	151,636	(9,735)	112,520	254,421
NET ASSETS - BEGINNING	1,034,679	315,616	710,918	2,061,213
NET ASSETS - ENDING	\$ 1,186,315	\$ 305,881	\$ 823,438	\$ 2,315,634

See accompanying notes.

FAMILIES OF SMA d/b/a CURE SMA
STATEMENTS OF CASH FLOWS
YEARS ENDED JUNE 30, 2017 AND 2016

	2017	2016
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 379,479	\$ 254,421
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	148,136	102,305
Bad debt expense	14,833	29,500
Net realized (gain) loss on investments	(2,991)	25,287
Net unrealized gain on investments	(72,220)	(12,179)
Contributions restricted for investment in endowment fund	(116,736)	(112,520)
Changes in operating assets and liabilities:		
Receivables	(385,190)	(30,727)
Prepaid expenses	(33,429)	(1,725)
Other assets	(16,998)	-
Accounts payable and accrued expenses	677,013	132,223
Grants payable	11,250	275,001
Total adjustments	223,668	407,165
Net cash provided by operating activities	603,147	661,586
CASH FLOWS FROM INVESTING ACTIVITIES:		
Capital expenditures	(148,463)	(56,667)
Proceeds on sales of investments	328,521	453,566
Purchases of investments	(431,615)	(579,216)
Net cash used in investing activities	(251,557)	(182,317)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions restricted for investment in endowment	116,736	112,520
NET INCREASE IN CASH AND CASH EQUIVALENTS	468,326	591,789
CASH AND CASH EQUIVALENTS - BEGINNING	2,658,075	2,066,286
CASH AND CASH EQUIVALENTS - ENDING	\$ 3,126,401	\$ 2,658,075
Supplemental Disclosure of Cash Flow Information:		
Interest paid	\$ -	\$ -
Income taxes paid	\$ -	\$ -

See accompanying notes.

FAMILIES OF SMA d/b/a CURE SMA
NOTES TO FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Purpose

Families of SMA d/b/a Cure SMA (the “Organization”) is a not-for-profit organization that is tax-exempt under the provisions of Internal Revenue Code 501(c) (3). The purpose of the Organization is to raise money for advancing research, to provide patient and family support, and to promote public awareness with regard to the disease Spinal Muscular Atrophy (“SMA”).

Basis of Presentation

The financial statements of the Organization have been prepared on the accrual basis of accounting. Net assets, revenues, expenses, gains and losses are classified based on the existence or absence of donor-imposed restrictions as follows:

- *Unrestricted* - net assets that are not subject to donor-imposed restrictions.
- *Temporarily restricted* - net assets subject to donor-imposed restrictions that may or will be met by actions of the Organization or that expire by the passage of time.
- *Permanently restricted* - net assets subject to donor-imposed restrictions that require the assets be maintained permanently by the Organization.

Restricted and Unrestricted Revenue and Support

Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support, depending on the existence and/or nature of any donor restrictions. Support that is restricted by the donor is reported as an increase in unrestricted net assets if the restriction expires in the reporting period in which the support is recognized. All other donor-restricted support is reported as an increase in temporarily or permanently restricted net assets, depending on the nature of the restriction. When a restriction expires (i.e. when a stipulated time restriction ends or purpose restriction is accomplished), restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions.

Cash and Cash Equivalents

Cash and cash equivalents include highly liquid short-term investments with remaining maturities at date of purchase of three months or less. Cash equivalents include investments in money market funds that are carried at cost plus accrued interest, which approximates fair value.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Investments

The Organization's investments are reported at their fair values in the statements of financial position. Investment income, including realized and unrealized gains and losses, interest and dividend income and investment expenses are included as a change in net assets in the statements of activities. Market risk is inherent and is dependent on the future changes in market prices of the investments held.

Fair Value Measurements

Fair value is defined as the price that the Organization would receive to sell an asset or pay to transfer a liability in an orderly transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is measured under a three-tier hierarchy to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs) and to establish a classification of fair value measurements for disclosure purposes.

Various inputs are used in determining the value of the Organization's assets and liabilities. The inputs are summarized in the three broad levels listed below.

Level 1 - quoted prices in active markets for identical assets or liabilities

Level 2 - other significant observable inputs (including quoted prices for similar assets or liabilities, interest rates, credit risk, etc.)

Level 3 - significant unobservable inputs (including the Organization's own assumptions in determining the fair value of assets or liabilities)

In applying the provisions of fair value measurements to the Organization's assets during the year, the following valuation techniques have been employed:

Exchange-Traded Funds

Exchange-traded funds traded on a national exchange or on the national market system of NASDAQ are valued at their last reported sale price or, if there has been no sale on that date, at the closing "bid" price if long, or closing "ask" price if short. Other exchange-traded funds for which over-the-counter market quotations are available are valued at their last reported sale price or, if there had been no sale on that date, at closing "bid" price if long, or closing "ask" price if short as reported by a reputable source selected by the Organization. The Organization has sole and absolute discretion in valuing any positions for which market quotations are not readily available or in adjusting the valuation of any other positions. The Organization's investments in exchange-traded funds are categorized in Level 1 of the fair value hierarchy.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Fair Value Measurements (Continued)***Mutual Funds***

Mutual funds are valued at their net asset values, which are determined daily and are quoted on a national exchange. The Organization's investments in mutual funds are categorized in Level 1 of the fair value hierarchy.

Revenue and Support Recognition

Revenue from donors is recognized at the time the unconditional pledge or donation is made. Chapter event and annual conference revenue is recognized at the time the event occurs. Industry collaboration income is recognized based on the pro-rata share of allocated costs incurred during the period, based on the agreed upon budget, and when determined to be realizable.

Receivables

Receivables that are expected to be collected within one year are recorded at net realizable value. Receivables that are expected to be collected in future years are recorded at fair value, using present value techniques and applicable discount rates. The discounts on the estimated future cash flows of receivables are computed using risk-free interest rates applicable to the years in which the receivables are received. Amortization of the discount is included in revenue. An allowance for uncollectible receivables is provided based upon management's judgment, including such factors as prior collection history, type of revenue and nature of fund raising activity. After all attempts to collect a receivable have failed, the receivable is written off against the allowance.

At June 30, 2017 and 2016, receivables from five and one supporter(s), respectively, accounted for approximately 73% and 18% of total receivables.

Property and Equipment

Property and equipment is recorded at cost, if purchased, and donated property is stated at fair market value at the date of contribution. Expenditures for major betterments and additions are charged to the asset accounts while replacements, maintenance and repairs, which do not improve or extend the lives of the respective assets, are charged to expense currently.

Depreciation of property and equipment is determined using the straight-line method, based on estimated useful lives of 3 to 7 years.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Costs Incurred to Develop or Obtain Computer Software for Internal Use

The Organization capitalizes the costs incurred during the application development stage, which include costs to design the software configuration and interfaces, coding, installation, and testing. Costs incurred during the preliminary project and post-implementation stages and costs incurred to maintain existing product offerings are expensed as incurred. Capitalized development costs are to be amortized over three years upon completion of project. The capitalization and ongoing assessment of recoverability of development costs requires considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility, and estimated economic life.

Functional Expenses

The costs of providing the Organization's various programs and other activities have been summarized on a functional basis. Direct costs are allocated specifically to the Organization's program and supporting services. Indirect costs are allocated by management to program and supporting services benefited based on the percentage of employee time spent among other factors. The allocation of costs is based on management's estimate, which is periodically reviewed to assess the appropriateness of the cost allocation.

Advertising and Promotion

Advertising and promotion costs are primarily related to fundraising events and press releases. These costs are expensed as incurred. For the years ended June 30, 2017 and 2016, advertising and promotion expense amounted to approximately \$136,000 and \$80,000, respectively, and is included as a component of program and supporting services in the accompanying statements of activities.

Concentration of Credit Risk

The Organization deposits excess cash with high credit quality financial institutions. At times, such balances may be in excess of federally insured limits. The Organization maintains their investment portfolio with one financial institution.

Donated Services and In-kind Contributions

The Organization records the value of donated services and supplies when there is an objective basis available to measure their value. For the years ended June 30, 2017 and 2016, the value of in-kind contributions meeting the requirements for recognition in the financial statements amounted to approximately \$371,000 and \$312,000, respectively, which is included as a component of contributions and chapter event related revenue in the statements of activities.

A substantial number of unpaid volunteers have donated services and made contributions of their time in connections with activities of the Organization. The value of these donated services are not reflected in the financial statements since they are not susceptible to objective measurement or valuation.

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Income Taxes

The Organization has been granted an exemption from income taxes under Internal Revenue Code Section 501(c)(3) as a non-profit corporation. Certain activities not directly related to the Organization's tax-exempt purpose could be subject to taxation as unrelated business income, however a provision for unrelated business income tax was not required.

The Organization assesses its tax positions in accordance with "*Accounting for Uncertainty in Income Taxes*," as prescribed by Accounting Standards Codification, which provides guidance for financial statements recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return for open tax years (generally a period of three years from the later of each return's due date or the date filed) that remain subject to examination by the Organization's major tax jurisdictions.

The Organization assesses its tax positions and determines whether it has any material unrecognized liabilities for uncertain tax positions. The Organization records these liabilities to the extent it deems them more likely than not to be incurred. Interest and penalties related to uncertain tax positions, if any, would be classified as a component of income tax expense. The Organization believes that it does not have any significant uncertain tax positions requiring recognition or measurement in the accompanying financial statements.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the statement of financial position dates and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Reclassification

Certain amounts in the 2016 financial statements have been reclassified to conform with 2017 presentation.

NOTE 2. INVESTMENTS AND FAIR VALUE MEASUREMENTS

The Organization's investments recorded at fair value have been categorized based upon a fair value hierarchy in accordance with the Organization's accounting policies as disclosed in Note 1. The following tables present information about the Organization's investments measured at fair value as of June 30th:

INVESTMENTS, at fair value	2017			Total
	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
Mutual funds:				
Fixed income - bond	\$ 335,051	\$ -	\$ -	\$ 335,051
Equity - mid cap	106,450	-	-	106,450
Alternative - long-short	91,534	-	-	91,534
Equity - international	65,502	-	-	65,502
Money market	43,115	-	-	43,115
Equity - small cap	40,910	-	-	40,910
Total mutual funds	682,562	-	-	682,562
Exchange-traded funds:				
Equity - index growth	159,841	-	-	159,841
Equity - index value	134,244	-	-	134,244
Equity - index international	45,379	-	-	45,379
Equity - small cap	10,287	-	-	10,287
Total exchange-traded funds	349,751	-	-	349,751
	\$ 1,032,313	\$ -	\$ -	\$ 1,032,313

NOTE 2. INVESTMENTS AND FAIR VALUE MEASUREMENTS (Continued)

INVESTMENTS, at fair value	2016			Total
	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
Mutual funds:				
Fixed income - bond	\$ 310,011	\$ -	\$ -	\$ 310,011
Equity - mid cap	73,249	-	-	73,249
Money market	61,941	-	-	61,941
Alternative - long-short	50,640	-	-	50,640
Equity - small cap	39,615	-	-	39,615
Equity - international	31,326	-	-	31,326
Total mutual funds	566,782	-	-	566,782
Exchange-traded funds:				
Equity - index value	125,415	-	-	125,415
Equity - index growth	112,966	-	-	112,966
Equity - index international	38,293	-	-	38,293
Equity - real estate	10,552	-	-	10,552
Total exchange-traded funds	287,226	-	-	287,226
	\$ 854,008	\$ -	\$ -	\$ 854,008

Endowment

The Organization maintains an endowment fund consisting of gifts restricted by donors and the board of directors for permanent investment. The Organization follows the Illinois Uniform Prudent Management of Institutional Funds Act (IUPMIFA) and its own governing documents. IUPMIFA requires the Organization to prudently manage its endowment fund. The majority of the Organization's endowment contributions are subject to a specific agreement with the Organization.

The Organization entered into an agreement with a donor to establish an endowment fund for the purpose of providing scholarships to attend the Organization's annual conference for any families of patients newly diagnosed with Spinal Muscular Atrophy. The agreement requires the following: (a) all earnings of the endowment fund are reinvested into the corpus of the endowment, (b) no withdrawals from the endowment fund are allowed if the fund balance is less than \$1,000,000, (c) up to 2.5% of the fund may be withdrawn, if the fund balance is above \$1,000,000 but less than \$2,000,000, so long as such withdrawal does not reduce the fund balance below \$1,000,000, (d) up to 5% of the fund may be withdrawn, if the fund balance is above \$2,000,000. Additionally, under the terms of the agreement, the board of directors designated \$30,000 of unrestricted net assets for the endowment fund.

NOTE 2. INVESTMENTS AND FAIR VALUE MEASUREMENTS (Continued)

The Organization's investment guidelines and policies are overseen by members of the finance committee reporting to the Organization's board of directors. The overall investment objective of the Organization is to maximize the return on invested assets while minimizing risk and expenses. This is done through prudent investing and planning, as well through the maintenance of a diversified portfolio. Investments shall be diversified with a view to minimizing risk. Investments in the equity securities of any one company shall not exceed 5% of the portfolio nor shall the total securities position (debt and equity) in any one company exceed 10% of the portfolio. No more than 25% of the entire portfolio may be invested in the securities of any one sector. The assets of the Organization have a long investment time horizon.

The primary investment objective of the portfolio is to grow the corpus in excess of inflation and to meet the current and future obligations as dictated by the Organization's spending objectives. This objective is to be achieved through the establishment of an optimal portfolio structure and through the retention of quality investment managers capable of meeting the specific performance goals of the Organization. The investment portfolio is expected to achieve the following over rolling five year periods: (a) provide an annualized rate of return that will support the spending policy net of inflation, (b) outperform the return of a hypothetical portfolio composed of indexes weighted according to the target allocation, (c) outperform the median manager in a universe of foundations and endowments, (d) the volatility of returns, as measured by the standard deviation of quarterly returns, should be comparable to that of the benchmark index.

Endowment net asset composition by type of fund is as follows as of June 30th:

	2017		
	Unrestricted	Permanently restricted	Total
Board-designated endowment funds	\$ 33,715	\$ -	\$ 33,715
Donor-restricted endowment funds	-	998,598	998,598
Total funds	\$ 33,715	\$ 998,598	\$ 1,032,313

	2016		
	Unrestricted	Permanently restricted	Total
Board-designated endowment funds	\$ 30,570	\$ -	\$ 30,570
Donor-restricted endowment funds	-	823,438	823,438
Total funds	\$ 30,570	\$ 823,438	\$ 854,008

NOTE 2. INVESTMENTS AND FAIR VALUE MEASUREMENTS (Continued)

Changes in endowment net assets are as follows for the years ended June 30th:

	2017		
	Unrestricted	Permanently restricted	Total net endowment assets
Endowment net assets, beginning of year	\$ 30,570	\$ 823,438	\$ 854,008
Contributions	-	116,736	116,736
Net unrealized gains	2,585	69,635	72,220
Other investment income, net	560	15,074	15,634
Amounts appropriated for expenditure	-	(26,285)	(26,285)
Endowment net assets, end of year	\$ 33,715	\$ 998,598	\$ 1,032,313

	2016		
	Unrestricted	Permanently restricted	Total net endowment assets
Endowment net assets, beginning of year	\$ 30,548	\$ 710,918	\$ 741,466
Contributions	-	112,008	112,008
Net unrealized gains	502	11,677	12,179
Other investment loss, net	(480)	(11,165)	(11,645)
Endowment net assets, end of year	\$ 30,570	\$ 823,438	\$ 854,008

NOTE 3. INVESTMENT INCOME, NET

Investment income, net is comprised of the following for the years ended June 30th:

	2017	2016
Net realized gains (losses)	\$ 2,991	(\$ 25,287)
Net unrealized gains	72,220	12,179
Interest and dividend income	19,344	19,250
Investment expenses	(6,701)	(5,608)
	\$ 87,854	\$ 534

NOTE 4. RECEIVABLES, NET

Receivables consisted of the following as of June 30th:

	2017	2016
Industry collaboration	\$ 125,246	\$ 74,165
Annual conference	217,241	60,000
Pledges	172,030	-
Other	37,000	61,662
	<u>551,517</u>	<u>195,827</u>
Less: allowance for doubtful accounts	(14,833)	(29,500)
	<u>\$ 536,684</u>	<u>\$ 166,327</u>

NOTE 5. PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the following as of June 30th:

	2017	2016
Medical equipment	\$ 150,484	\$ 458,633
Software	148,140	148,140
Office equipment	53,879	58,343
Office furniture	28,561	42,676
	<u>381,064</u>	<u>707,792</u>
Less: accumulated depreciation and amortization	(165,107)	(492,162)
	<u>\$ 215,957</u>	<u>\$ 215,630</u>

Depreciation and amortization expense for the years ended June 30, 2017 and 2016, amounted to approximately \$148,000 and \$102,000, respectively.

NOTE 6. GRANTS PAYABLE

The Organization makes grants to various medical and research centers for research in relation to Spinal Muscular Atrophy. Grant agreements are subject to periodic reporting and compliance requirements and can be rescinded by the Organization if it is determined that a research project is no longer academically, technically or commercially feasible. The Organization is responsible for all costs incurred or committed at the time of termination. Research grant expense for the years ended June 30, 2017 and 2016, amounted to approximately \$1,548,000 and \$1,220,000, respectively, and is included as a component of research in the accompanying statements of activities.

NOTE 6. GRANTS PAYABLE (Continued)

As of June 30, 2017, the Organization's grants payable obligations have terms expiring through February 2019. As of June 30, 2017 and 2016, grants payable obligations amounted to approximately \$990,000 and \$979,000, respectively.

Future obligations associated with the Organization's grants payable for fiscal years subsequent to June 30, 2017 are as follows:

2018	\$	762,500
2019		227,500
	\$	990,000

Certain grant payments are made to grantees based on research milestones being met. These obligations are not accrued since conditional promises to give are not recognized until the conditions are substantially met. The timing of the research and development milestones being met and certainty of future grant payments is generally not readily determinable. During the years ended June 30, 2017 and 2016, certain research and development milestones were achieved and payments related to conditional promises were disbursed in the amounts of \$87,500 and \$175,000, respectively, which are included as a component of research in the accompanying statements of activities.

As of June 30, 2017, future conditional promises due to grantees based on the achievement of milestones are estimated to be \$342,000.

NOTE 7. NET ASSET RESTRICTIONS

At June 30, 2017 and 2016, temporarily restricted net assets amounted to approximately \$484,000 and \$306,000, respectively, and are primarily restricted for research grants.

At June 30, 2017 and 2016, permanently restricted net assets amounted to approximately \$999,000 and \$823,000, respectively, and are restricted for a scholarship fund endowment.

NOTE 8. CHAPTERS

The Organization has established Chapters consisting of volunteers who promote local and regional fund-raising and outreach efforts for the Organization by hosting events in their respective states and regions. As of June 30, 2017, there are thirty-one active chapters throughout the United States. Fund-raising and patient service support activities are coordinated by the staff of the Organization and revenue and expenses related to all such activities are included in the accompanying statements of activities.

NOTE 9. COMMITMENTS AND CONTINGENCIES

Economic Conditions

The Organization depends substantially on contributions for its revenues. The ability of certain Organization contributors to continue giving amounts comparable with prior years may be dependent upon current and future overall economic conditions. While the Organization's board of directors believes the Organization has the resources to continue its programs, its ability to do so and the extent to which it continues, may be dependent on the above factors.

Legal Matters

Management does not believe there is any litigation threatened against the Organization other than routine contractual matters arising in the ordinary course of its activities, none of which are expected to have a material adverse effect on the accompanying financial statements of the Organization.

Lease Commitments

The Organization leases office space for its headquarters located in Elk Grove Village, Illinois, expiring February 2022, and a satellite office located in Chicago, Illinois, expiring January 2020. The approximate future minimum lease payments under the non-cancelable operating leases for fiscal years subsequent to June 30, 2017 are summarized below:

2018	\$	161,000
2019		165,000
2020		123,000
2021		62,000
2022		43,000
	\$	554,000

Rent expense, including common area maintenance costs, for the years ended June 30, 2017 and 2016 amounted to approximately \$129,000 and \$75,000, respectively.

NOTE 10. SUBSEQUENT EVENTS

The Organization has evaluated subsequent events through November 7, 2017 which is the date the accompanying financial statements were available to be issued.

**SUPPLEMENTARY INFORMATION
AND REPORT ON COMPLIANCE**

FAMILIES OF SMA d/b/a CURE SMA
SCHEDULE OF FUNCTIONAL EXPENSES
YEAR ENDED JUNE 30, 2017

	Program Services				Supporting Services				Total
	Research	Patient Services	Family Support	Awareness	Total Program Services	General and Administrative	Fund Raising and Event Related	Total Supporting Services	
SALARIES AND RELATED EXPENSES:									
Salaries	\$ 564,178	\$ 253,219	\$ 420,493	\$ 264,602	\$ 1,502,492	\$ 138,399	\$ 475,857	\$ 614,256	\$ 2,116,748
Retirement plan	10,083	4,021	6,424	3,424	23,952	2,005	6,172	8,177	32,129
Payroll taxes	44,013	20,571	33,207	22,245	120,036	12,459	38,971	51,430	171,466
Total salaries and related expenses	618,274	277,811	460,124	290,271	1,646,480	152,863	521,000	673,863	2,320,343
NON-PERSONNEL EXPENSES:									
Research grants	1,548,209	-	-	-	1,548,209	-	-	-	1,548,209
Fundraising events	34,582	33,453	224,610	164,741	457,386	46	404,707	404,753	862,139
Fundraising events - in kind			74,247	74,247	148,494	-	222,742	222,742	371,236
Conferences and meetings	564,179	301,500	323,908	32,284	1,221,871	70,009	85,917	155,926	1,377,797
Professional fees	152,111	164,143	66,890	30,569	413,713	47,261	31,725	78,986	492,699
Merchandise	-	-	4,775	4,775	9,550	-	14,323	14,323	23,873
Postage and delivery	26,951	17,159	37,250	12,337	93,697	2,674	18,266	20,940	114,637
Website	5,736	5,736	40,149	34,414	86,035	5,736	22,942	28,678	114,713
Office	21,956	8,813	46,599	10,125	87,493	5,395	17,510	22,905	110,398
Insurance	25,205	23,703	42,484	22,907	114,299	10,350	38,051	48,401	162,700
Rent	35,991	11,568	25,707	16,710	89,976	8,998	29,563	38,561	128,537
Bank and credit card fees	5,284	912	18,740	18,092	43,028	9,116	41,286	50,402	93,430
Miscellaneous	3,381	1,252	5,429	1,145	11,207	1,192	16,899	18,091	29,298
Telephone	6,918	2,173	4,859	3,167	17,117	1,692	5,563	7,255	24,372
Utilities	5,588	1,824	4,451	2,643	14,506	1,379	4,625	6,004	20,510
Advertising and media	38,596	12,098	27,079	18,146	95,919	9,414	30,894	40,308	136,227
Total non-personnel expenses	2,474,687	584,334	947,177	446,302	4,452,500	173,262	985,013	1,158,275	5,610,775
Total expenses before depreciation and amortization	3,092,961	862,145	1,407,301	736,573	6,098,980	326,125	1,506,013	1,832,138	7,931,118
Depreciation and amortization	6,664	86,949	6,815	30,669	131,097	3,408	13,631	17,039	148,136
Total expenses	\$ 3,099,625	\$ 949,094	\$ 1,414,116	\$ 767,242	\$ 6,230,077	\$ 329,533	\$ 1,519,644	\$ 1,849,177	\$ 8,079,254

See independent auditors' report.

FAMILIES OF SMA d/b/a CURE SMA
SCHEDULE OF FUNCTIONAL EXPENSES
YEAR ENDED JUNE 30, 2016

	Program Services				Supporting Services				Total
	Research	Patient Services	Family Support	Awareness	Total Program Services	General and Administrative	Fund Raising and Event Related	Total Supporting Services	
SALARIES AND RELATED EXPENSES:									
Salaries	\$ 261,478	\$ 162,991	\$ 377,469	\$ 218,544	\$ 1,020,482	\$ 109,248	\$ 394,522	\$ 503,770	\$ 1,524,252
Payroll taxes	20,812	13,703	29,477	17,962	81,954	9,761	31,143	40,904	122,858
Total salaries and related expenses	282,290	176,694	406,946	236,506	1,102,436	119,009	425,665	544,674	1,647,110
NON-PERSONNEL EXPENSES:									
Research grants	1,219,840	-	-	-	1,219,840	-	-	-	1,219,840
Fundraising events	60,437	28,016	167,020	169,472	424,945	12,883	431,226	444,109	869,054
Fundraising events - in kind	-	-	62,392	62,392	124,784	-	187,182	187,182	311,966
Conferences and meetings	294,228	164,961	256,966	20,225	736,380	746	39,703	40,449	776,829
Professional fees	182,686	149,792	60,809	28,031	421,318	96,741	33,133	129,874	551,192
Merchandise	-	-	6,692	6,692	13,384	-	20,075	20,075	33,459
Postage and delivery	13,664	28,127	37,240	12,970	92,001	2,302	20,561	22,863	114,864
Website	6,311	6,311	44,168	37,809	94,599	6,310	25,286	31,596	126,195
Office	6,421	4,097	8,033	4,874	23,425	6,945	9,908	16,853	40,278
Insurance	9,334	15,158	33,382	20,146	78,020	6,545	31,804	38,349	116,369
Rent	11,610	9,914	17,143	11,389	50,056	5,635	19,578	25,213	75,269
Bank and credit card fees	-	153	15,863	15,191	31,207	3,949	42,473	46,422	77,629
Miscellaneous	2,641	5,470	9,937	9,592	27,640	5,083	25,527	30,610	58,250
Telephone	2,905	2,517	4,646	2,905	12,973	1,356	5,035	6,391	19,364
Utilities	1,901	1,630	3,421	1,956	8,908	888	3,377	4,265	13,173
Advertising and media	12,960	10,531	18,184	12,068	53,743	6,358	19,430	25,788	79,531
Miscellaneous patient services	38	8,276	34,315	254	42,883	18	712	730	43,613
Total non-personnel expenses	1,824,976	434,953	780,211	415,966	3,456,106	155,759	915,010	1,070,769	4,526,875
Total expenses before depreciation and amortization	2,107,266	611,647	1,187,157	652,472	4,558,542	274,768	1,340,675	1,615,443	6,173,985
Depreciation and amortization	5,680	51,186	5,680	25,559	88,105	2,840	11,360	14,200	102,305
Total expenses	\$ 2,112,946	\$ 662,833	\$ 1,192,837	\$ 678,031	\$ 4,646,647	\$ 277,608	\$ 1,352,035	\$ 1,629,643	\$ 6,276,290

See independent auditors' report.

**INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER
FINANCIAL REPORTING AND ON COMPLIANCE BASED ON AN AUDIT OF
FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH
GOVERNMENT AUDITING STANDARDS**

Families of SMA d/b/a Cure SMA
Elk Grove, Illinois

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Families of SMA d/b/a Cure SMA (the "Organization"), which comprise the statement of financial position as of June 30, 2017, and the related statements of activities and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated November 7, 2017.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Organization's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatements of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.


Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance

As part of obtaining reasonable assurance about whether the Organization’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statements amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



Kaufman, Rossin & Co., P.A.

November 7, 2017
Miami, Florida